Loading organizations...
Key people at Formula Pharmaceuticals.
Formula Pharmaceuticals was a privately held biotechnology company focused on the advancement of clinical-stage oncology drug development, operating out of its headquarters in Berwyn, Pennsylvania. The enterprise operated within the cancer therapeutics sector, utilizing venture funding support to research and develop specialized medical treatments for patients facing severe oncological conditions. Throughout its corporate lifecycle, the firm worked to progress its proprietary clinical pipeline while building out its executive leadership team, notably appointing Dr. Wolfgang Oster as Chairman of the Board in February 2012. Following several years of independent clinical research and therapeutic development in the biotechnology space, the business transitioned its assets and operations through a strategic corporate transaction, officially merging with CoImmune, Inc. on April 30, 2020. Formula Pharmaceuticals was originally established as an independent corporate entity in 2009 by currently undisclosed founders.
Key people at Formula Pharmaceuticals.
Formula Pharmaceuticals, Inc. was a privately held, immuno-oncology company based in Berwyn, Pennsylvania, focused on developing CAR immunotherapy for oncology and autoimmune diseases using a proprietary non-viral, allogeneic CIR-CIK (Cytokine Induced Killer) technology platform.[1][4] This platform aimed to improve upon existing CAR-T approaches by enhancing patient access, clinical benefits, and manufacturing cost-effectiveness, targeting hematologic cancers like acute lymphoblastic leukemia and solid tumors.[1][2] The company served patients with unmet needs in oncology, addressing limitations of autologous CAR-T therapies that rely on viral transduction and patient-specific cells, but it merged into CoImmune, Inc. in 2020, ceasing independent operations.[2][3][4]
Founded in 2009 and headquartered in Berwyn, PA, Formula Pharmaceuticals emerged as a biotech innovator in the immuno-oncology space.[4] Specific founders and early backstory details are not detailed in available sources, but the company quickly advanced a non-viral Sleeping Beauty transposon-based gene transfer system for CAR-CIK cells.[1] A pivotal moment came in its strategic collaboration with the Max Delbrück Center for Molecular Medicine (MDC), securing an exclusive license for MDC's SB100X transposase to develop CIK-based CAR immunotherapies.[1] This partnership highlighted early traction in allogeneic cell therapies, culminating in the 2020 merger with CoImmune, accompanied by a $6 million investment to advance the CAR-CIK program.[2][3]
Formula stood out in the crowded CAR therapy field through these key advantages:
Post-merger, these assets integrated into CoImmune's portfolio, enhancing its immuno-oncology offerings.[2][3]
Formula rode the explosive growth of cell therapies in the 2010s, capitalizing on CAR-T approvals like Kymriah and Yescarta while addressing their key pain points—high costs, manufacturing complexity, and limited scalability.[1][2] Its timing aligned with the shift toward allogeneic platforms, as market forces favored "off-the-shelf" solutions amid rising demand for accessible cancer immunotherapies.[2] By merging into CoImmune, Formula influenced the ecosystem by broadening pipelines (e.g., combining with CoImmune's CMN-001 dendritic cell therapy), fostering South Korean-US biotech synergies via SCM Lifescience and Genexine funding, and advancing CIK-based tech toward FDA trials in renal carcinoma and leukemia.[2][3] This contributed to the evolution of next-gen CARs, reducing reliance on patient-derived cells.
Formula's legacy endures through CoImmune, which absorbed its CAR-CIK platform to pursue Phase 2b trials for CMN-001 in renal carcinoma and CIK therapies in leukemia, backed by recent investments.[2][3] Next steps likely involve clinical readouts, pipeline expansion into solid tumors, and potential FDA milestones, shaped by trends like non-viral engineering and combo immunotherapies. As allogeneic CARs mature, CoImmune's integrated assets position it to capture market share in a sector projected to grow amid immunotherapy dominance—echoing Formula's original mission to democratize access to transformative cancer treatments.[1][2]
